AstraZeneca Pharma Share Price Falls 0.50 Percent Despite CDSCO Nod for Trastuzumab Deruxtecan Import

AstraZeneca Pharma share price Rs 8,127.15, down Rs 40.75 or 0.50 percent. Day high Rs 8,143.30, day low Rs 8,100.00. Volume 87 shares versus 5-day average 447 shares.

AstraZeneca Pharma share price slipped on 28 July 2026 even as the company secured a fresh regulatory clearance for one of its oncology products in India. The stock was quoting at Rs 8,127.15, down Rs 40.75 or 0.50 percent, with the mild decline coming despite the positive regulatory development.

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organization, Directorate General of Health Services, Government of India to import for sale and distribution of Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion for an additional indication.

Click Here – Get Free Investment Predictions

Astrazeneca Pharma Share Price Today: Key Trading Levels

AstraZeneca Pharma share price touched an intraday high of Rs 8,143.30 and an intraday low of Rs 8,100.00 during Tuesday’s session, a relatively narrow range for the stock. It was trading with volumes of just 87 shares, compared to its five day average of 447 shares, a decrease of 80.55 percent, reflecting a very thin session with limited overall participation.

Check Live Stock Screener for More Pharma Sector Picks

What the CDSCO Approval Covers

Trastuzumab Deruxtecan is an antibody-drug conjugate used in oncology treatment, and the CDSCO clearance allows AstraZeneca Pharma India to import the 100mg/5mL lyophilized powder formulation for an additional indication beyond its existing approved uses in the country. Expanding approved indications for an existing oncology product typically widens the eligible patient population that can be treated with the drug in India.

AstraZeneca Pharma share price muted reaction on the day suggests the market treated the additional indication approval as a routine regulatory update rather than a material near-term earnings trigger, consistent with the very low trading volumes seen during the session.

Why CDSCO Approvals Matter for Pharma Companies in India

Regulatory clearances from the Central Drugs Standard Control Organization are a necessary step before any pharmaceutical company can legally import, manufacture, or distribute a specific drug formulation in India, and additional indication approvals for existing products typically follow the submission of supporting clinical trial data to the regulator. This process ensures that new uses for already-approved medicines meet the same safety and efficacy standards required for the original approval.

AstraZeneca Pharma India markets a range of specialty products across oncology, cardiovascular, and respiratory therapy areas in the Indian market, with its oncology franchise increasingly featuring advanced biologics and antibody-drug conjugates such as Trastuzumab Deruxtecan as part of the company’s broader specialty care strategy in the country. Expanded approvals of this kind typically follow a period of clinical evaluation and regulatory review before Indian patients gain access to the additional indication.

Download the Univest iOS App or Univest Android App to track AstraZeneca Pharma share price movements live and get regulatory approval alerts.

Conclusion

AstraZeneca Pharma share price eased 0.50 percent to Rs 8,127.15 on 28 July 2026 even after the company received CDSCO permission to import Trastuzumab Deruxtecan for an additional indication, with the stock’s decline appearing unrelated to the regulatory news given the very thin trading volumes. Investors tracking AstraZeneca Pharma share price should evaluate the company’s broader oncology pipeline and consult a SEBI-registered investment advisor before making any investment decision.

FAQs

Why did AstraZeneca Pharma share price fall despite the CDSCO nod?

Ans. AstraZeneca Pharma share price fell 0.50 percent to Rs 8,127.15 on very thin trading volumes, with the decline appearing largely unrelated to the CDSCO approval for Trastuzumab Deruxtecan import.

What did AstraZeneca Pharma India receive CDSCO approval for?

Ans. AstraZeneca Pharma India received CDSCO permission to import for sale and distribution of Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for an additional indication.

What was the intraday range for AstraZeneca Pharma share price today?

Ans. AstraZeneca Pharma share price touched an intraday high of Rs 8,143.30 and an intraday low of Rs 8,100.00 during the session on 28 July 2026.

What was the trading volume for AstraZeneca Pharma share price today?

Ans. AstraZeneca Pharma share price traded with volumes of just 87 shares, compared to its five day average of 447 shares, a decrease of 80.55 percent.

What is Trastuzumab Deruxtecan used for?

Ans. Trastuzumab Deruxtecan is an antibody-drug conjugate used in oncology treatment, and the CDSCO approval expands its permitted use to an additional indication in India.

Is AstraZeneca Pharma share price a good buy after the CDSCO approval?

Ans. Investors should evaluate AstraZeneca Pharma share price alongside the company’s broader oncology portfolio, valuation, and sector trends, and consult a SEBI-registered investment advisor before making any buy, hold, or sell decisions.

Which authority granted the import approval to AstraZeneca Pharma India?

Ans. The Central Drugs Standard Control Organization, Directorate General of Health Services, Government of India, granted the import approval.